|Bid||149.594 x 20000|
|Ask||149.771 x 20000|
|Day's range||148.877 - 148.877|
|52-week range||104.249 - 152.803|
|PE ratio (TTM)||19.88|
|Dividend & yield||0.04 (0.03%)|
|1y target est||N/A|
Credit Suisse We initiate coverage of Anthem with a Neutral rating and $195 target price. Following Anthem’s (ANTM) failed acquisition of Cigna (CI) and with the Affordable Care Act’s exchanges and Medicaid expansion facing an uncertain future, the Anthem investment story is now entering a new chapter. It is improving its execution in its historically underperforming Medicare Advantage (MA) business, making recent strides on membership growth, margins, and Stars.
The stock of Cigna (CI) hit a 52-week high of $173.44. The rise in the stock is believed to have been driven by an acquisition, its detailed long-term growth plans.